RU2007123253A - Производные тетералина и индана и их применения - Google Patents

Производные тетералина и индана и их применения Download PDF

Info

Publication number
RU2007123253A
RU2007123253A RU2007123253/04A RU2007123253A RU2007123253A RU 2007123253 A RU2007123253 A RU 2007123253A RU 2007123253/04 A RU2007123253/04 A RU 2007123253/04A RU 2007123253 A RU2007123253 A RU 2007123253A RU 2007123253 A RU2007123253 A RU 2007123253A
Authority
RU
Russia
Prior art keywords
compound
compound according
benzenesulfonyl
value
piperazine
Prior art date
Application number
RU2007123253/04A
Other languages
English (en)
Other versions
RU2389723C2 (ru
Inventor
III Ральф Нью ХАРРИС (US)
III Ральф Нью ХАРРИС
Ненси Элизабет КРАУСС (US)
Ненси Элизабет КРАУСС
Джеймс М. КРЕСС (US)
Джеймс М. КРЕСС
Девид Брюс РЕПКЕ (US)
Девид Брюс РЕПКЕ
Расселл Стефен СТАБЛЕР (US)
Расселл Стефен СТАБЛЕР
Original Assignee
Ф. Хоффманн-Ля Рош Аг (Ch)
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг (Ch), Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг (Ch)
Publication of RU2007123253A publication Critical patent/RU2007123253A/ru
Application granted granted Critical
Publication of RU2389723C2 publication Critical patent/RU2389723C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (29)

1. Соединение формулы I
Figure 00000001
;
или его фармацевтически приемлемая соль,
где m имеет значение от 0 до 3;
р имеет значение от 1 до 3;
q имеет значение 0, 1 или 2;
Ar представляет собой возможно замещенный арил или возможно замещенный 5-12-членный гетероарил;
каждый R1 независимо представляет собой галогено, С1-12-алкил, C1-12-галогеноалкил, C1-12-гетероалкил, циано, -S(O)t-Ra, -C(=О)-NRbRc, -SO2-NRbRc, -N(Rd)-C(=O)-Re или -C(=O)-Re, где t имеет значение от 0 до 2, каждый из Ra, Rb, Rc и Rd независимо представляет собой водород или C1-12-алкил и Re представляет собой водород, C1-12-алкил, C1-12-алкокси или гидрокси;
R2 представляет собой
Figure 00000002
;
каждый из n и r независимо имеет значение 1 или 2; и
Х представляет собой -NR3, когда n имеет значение 2, или Х представляет собой -CHNR4R5, когда n имеет значение 1 или 2, где каждый из R3, R4 и R5 независимо представляет собой водород или метил,
при условии, что исключен 4-(4-хлорфенилтио)-1-(метилпиперазино)индан.
2. Соединение по п.1, где р имеет значение 1 или 2.
3. Соединение по п.2, где q имеет значение 2.
4. Соединение по п.1, где n имеет значение 2.
5. Соединение по п.3, где Х представляет собой -NR3.
6. Соединение по п.5, где r имеет значение 1.
7. Соединение по п.6, где Ar представляет собой возможно замещенный арил.
8. Соединение по п.7, где Ar представляет собой возможно замещенный фенил.
9. Соединение по п.8, где R3 представляет собой водород.
10. Соединение по п.8, где R3 представляет собой метил.
11. Соединение по п.5, где R2 представляет собой
Figure 00000003
;
Figure 00000004
или
Figure 00000005
,
где каждый из R3, R4 и R5 независимо представляет собой водород или метил.
12. Соединение по п.1, где указанное соединение представляет собой соединение формулы II
Figure 00000006
;
и где m, p, Ar, R1 и R3 являются такими, как изложено в п.1.
13. Соединение по п.12, где p имеет значение 1 или 2.
14. Соединение по п.13, где q имеет значение 2.
15. Соединение по п.14, где Ar представляет собой возможно замещенный арил.
16. Соединение по п.15, где Ar представляет собой возможно замещенный фенил.
17. Соединение по п.16, где R3 представляет собой водород.
18. Соединение по п.16, где R3 представляет собой метил.
19. Соединение по п.1, где указанное соединение представляет собой соединение формулы IIIа или IIIб
Figure 00000007
;
Figure 00000008
;
где s имеет значение от 0 до 4;
каждый R6 независимо представляет собой галогено, C1-12-алкил, С1-12-галогеноалкил, C1-12-гетероалкил, циано, -S(O)t-Ra, -C(=O)-NRbRc, -SO2-NRbRc, -N(Rd)-C(=O)-Re или -C(=O)-Re, где t имеет значение от 0 до 2, каждый из Ra, Rb, Rc и Rd независимо представляет собой водород или C1-12-алкил и Re представляет собой водород, C1-12-алкил, C1-12-алкокси или гидрокси; и
R3 является таким, как изложено в п.1.
20. Соединение по п.19, где s имеет значение от 0 до 2 и каждый R6 независимо представляет собой галогено, C1-12-алкил, C1-12-алкокси или C1-12-галогеноалкил.
21. Соединение по п.19, где указанное соединение представляет собой соединение формулы IIIа.
22. Соединение по п.21, где R3 представляет собой водород.
23. Соединение по п.21, где R3 представляет собой метил.
24. Соединение по п.21, где s имеет значение 0 или 1 и R6 представляет собой галогено.
25. Соединение по п.1, где указанное соединение выбрано из
1-(5-бензолсульфонил-индан-1-ил)-пиперазина;
1-(5-бензолсульфонил-индан-1-ил)-пирролидин-3-иламина;
1-[5-(4-фтор-бензолсульфонил)-индан-1-ил]-пиперазина;
1-[5-(2-фтор-бензолсульфонил)-индан-1-ил]-пиперазина;
1-[5-(3-хлор-бензолсульфонил)-индан-1-ил]-пиперазина;
1-[5-(3-хлор-бензолсульфонил)-индан-1-ил]-пиперидин-4-иламина;
1-(7-бензолсульфонил-1,2,3,4-тетрагидро-нафталин-1-ил)-пиперазина;
1-(6-бензолсульфонил-1,2,3,4-тетрагидро-нафталин-1-ил)-пиперазина;
1-[6-(4-фтор-бензолсульфонил)-1,2,3,4-тетрагидро-нафталин-1-ил]-пиперазина;
1-(6-бензолсульфонил-1,2,3,4-тетрагидро-нафталин-1-ил)-пиперидин-4-иламина и
1-(6-бензолсульфонил-1,2,3,4-тетрагидро-нафталин-1-ил)-4-метил-пиперазина.
26. Фармацевтическая композиция, содержащая эффективное количество соединения по п.1 в смеси с фармацевтически приемлемым носителем.
27. Применение соединения формулы I по п.1 в приготовлении лекарства, полезного в лечении болезненного состояния центральной нервной системы.
28. Применение по п.27, где болезненное состояние центральной нервной системы выбрано из психозов, шизофрении, маниакальных депрессий, неврологических расстройств, нарушений памяти, синдрома дефицита внимания, болезни Паркинсона, бокового амиотрофического склероза, болезни Альцгеймера, расстройств приема пищи и болезни Хантингтона.
29. Применение соединения формулы I по п.1 в приготовлении лекарства, полезного в лечении расстройства желудочно-кишечного тракта.
RU2007123253/04A 2004-12-21 2005-12-12 Производные тетралина и индана и их применения RU2389723C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63783604P 2004-12-21 2004-12-21
US60/637,836 2004-12-21

Publications (2)

Publication Number Publication Date
RU2007123253A true RU2007123253A (ru) 2009-01-27
RU2389723C2 RU2389723C2 (ru) 2010-05-20

Family

ID=35636804

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007123253/04A RU2389723C2 (ru) 2004-12-21 2005-12-12 Производные тетралина и индана и их применения

Country Status (14)

Country Link
US (1) US7473690B2 (ru)
EP (1) EP1831189B1 (ru)
JP (1) JP2008524274A (ru)
KR (1) KR100899061B1 (ru)
CN (1) CN101124210A (ru)
AT (1) ATE448216T1 (ru)
AU (1) AU2005318595B2 (ru)
BR (1) BRPI0515835A (ru)
CA (1) CA2591793A1 (ru)
DE (1) DE602005017663D1 (ru)
ES (1) ES2332526T3 (ru)
MX (1) MX2007007481A (ru)
RU (1) RU2389723C2 (ru)
WO (1) WO2006066745A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0713742A2 (pt) * 2006-06-20 2013-02-13 Hoffmann La Roche derivados de arilsulfonila naftaleno e usos destes
KR101770979B1 (ko) * 2010-05-21 2017-08-24 애브비 인코포레이티드 5­ｈｔ 수용체의 조절제 및 이의 사용방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
US5506192A (en) * 1990-06-07 1996-04-09 Sandoz Ltd. Substituted phthalides and heterocyclic phthalides
US5322851A (en) * 1990-07-02 1994-06-21 H. Lundbeck A/S Indole derivatives
JP3210665B2 (ja) * 1990-07-27 2001-09-17 中外製薬株式会社 新規なベンゾピラン誘導体
US5401848A (en) 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
US5817693A (en) * 1991-11-05 1998-10-06 Cousins; Russell Donovan Endothelin receptor antagonists
ZA93436B (en) * 1992-01-24 1993-08-25 Chugai Pharmaceutical Co Ltd Benzopyran derivatives
AU4761693A (en) * 1992-08-17 1994-03-15 Chugai Seiyaku Kabushiki Kaisha Benzopyran and benzoxazine derivatives
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
GB9226532D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6150402A (en) * 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
US5869478A (en) * 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
PL324319A1 (en) 1995-06-30 1998-05-25 Upjohn Co 1,6-disubstituted isochromates for fighting against sick headaches
US5663194A (en) * 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
JP2000514060A (ja) * 1996-07-01 2000-10-24 シェーリング コーポレイション ムスカリン様アンタゴニスト
US6214881B1 (en) * 1996-08-21 2001-04-10 Smithkline Beecham Corporation IL-8 receptor antagonists
US6559144B2 (en) * 1997-02-13 2003-05-06 Merck Patent Gesellschaft Mit Bicyclic amino acids
PT971878E (pt) * 1997-02-27 2008-07-08 Takeda Pharmaceutical Compostos de amina, sua produção e utilização como inibidores da produção de amilóide beta
TWI242011B (en) * 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
GB9726736D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Chemical compounds
FR2778662B1 (fr) 1998-05-12 2000-06-16 Adir Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HU226652B1 (en) * 1998-12-04 2009-05-28 Takeda Pharmaceutical Benzofuran derivatives, process for preparation of the same and uses thereof
GB9914024D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
ES2312423T3 (es) * 2000-04-03 2009-03-01 Takeda Pharmaceutical Company Limited Procedimiento para producir derivados de amina.
AR035858A1 (es) * 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
CA2452743A1 (en) * 2001-08-03 2003-02-13 Pharmacia & Upjohn Company 5-arylsulfonyl indoles having 5-ht6 receptor affinity
US20030064779A1 (en) * 2001-09-28 2003-04-03 Konami Gaming, Inc. Video slot gaming machine
MXPA04003087A (es) * 2001-10-04 2004-09-06 Wyeth Corp Derivados de cromano como ligados de 5-hidroxitriptamina-6.
WO2003029239A1 (en) * 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
EP1456178A1 (en) * 2001-12-21 2004-09-15 Smithkline Beecham Plc 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
US7795242B2 (en) * 2003-10-15 2010-09-14 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20070208166A1 (en) 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use

Also Published As

Publication number Publication date
JP2008524274A (ja) 2008-07-10
WO2006066745A1 (en) 2006-06-29
DE602005017663D1 (de) 2009-12-24
KR20070088797A (ko) 2007-08-29
ES2332526T3 (es) 2010-02-08
EP1831189B1 (en) 2009-11-11
CN101124210A (zh) 2008-02-13
MX2007007481A (es) 2007-07-20
RU2389723C2 (ru) 2010-05-20
US7473690B2 (en) 2009-01-06
AU2005318595A1 (en) 2006-06-29
ATE448216T1 (de) 2009-11-15
CA2591793A1 (en) 2006-06-29
BRPI0515835A (pt) 2008-08-12
EP1831189A1 (en) 2007-09-12
AU2005318595B2 (en) 2011-03-03
KR100899061B1 (ko) 2009-05-25
US20060160825A1 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
RU2403251C2 (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70
RU2007123251A (ru) Производные хромана и их применение в качестве лигандов 5-нт рецептора
AR060046A1 (es) Derivados de 2, 4-dioxo-1, 4-dihidropirido[2, 3 -d]pirimidina, un proceso para prepararlos e intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por pde4
RU2007122406A (ru) Производные тетралина и индана и их применения в качестве антагонистов 5-нт
CY1120169T1 (el) Παραγωγο αμιδιου και φαρμακο
JP2011519854A5 (ru)
MXPA04003007A (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
RU2372348C2 (ru) Производные индолилмалеимида в качестве ингибиторов ркс
NZ630467A (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
HRP20020712B1 (hr) Farmaceutske strukture koje sadrže derivate azetidina, novi derivati azetidina i njihovo pripremanje
CA2651363A1 (en) Triazolopyrazine derivatives useful as anti-cancer agents
CA2593264A1 (en) Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
RU2009120389A (ru) Гетероциклические соединения в качестве противовоспалительных агентов
JP2012510502A5 (ru)
AR062965A1 (es) Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos
PT98608A (pt) Processo para a preparacao de bifenilcarbonitrilos e de derivados de imidazol e de quinolina
MX2009013335A (es) Derivados de piperidina/piperazina.
RU2009117705A (ru) Производные 2-аминокарбонилпиридина
RU2009139915A (ru) Производные имидазолидинона
WO2008155668A3 (en) Heteroarylamide pyrimidone compounds
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
CA2748319A1 (en) Substituted quinazoline compounds of general formula (i) and uses thereof for treating disorders relating to tyrosine kinase dysregulation
CA2527315A1 (en) Imidazole derivatives as glutamate receptor antagonists
RU2007123253A (ru) Производные тетералина и индана и их применения
CA2587891A1 (en) 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)alylpiperazine derivatives

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20111213